Research

Hormonal

Chronic mirabegron treatment increases plasma levels of HDL cholesterol, ApoA1, and bile acids, independent of weight loss.

Mirabegron treatment improved favorable lipid markers (HDL, ApoA1) and bile acids. This may be a downstream effect of increased brown fat activity consuming lipoproteins. This benefit occurred without weight loss.

ModerateSupportsMEDIUM confidence
We observed increased fasting levels of the following: HDL (+8%), apolipoprotein A1 (ApoA1) (+12%)... total bile acids (+49%).
Alana O’Mara et al. · Journal of Clinical Investigation · 2020

Why this rating

Small sample size and lack of placebo control.

Source

Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity

Alana O’Mara et al. · Journal of Clinical Investigation · 2020

DOI 10.1172/jci131126

rct · n=14Cited 363×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →